AR011726A1 - Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento - Google Patents
Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimientoInfo
- Publication number
- AR011726A1 AR011726A1 ARP980102089A ARP980102089A AR011726A1 AR 011726 A1 AR011726 A1 AR 011726A1 AR P980102089 A ARP980102089 A AR P980102089A AR P980102089 A ARP980102089 A AR P980102089A AR 011726 A1 AR011726 A1 AR 011726A1
- Authority
- AR
- Argentina
- Prior art keywords
- cox
- acids
- procedure
- activity
- prevention
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 3
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 5
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- 150000007513 acids Chemical class 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 235000011054 acetic acid Nutrition 0.000 abstract 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- PUXBGTOOZJQSKH-UHFFFAOYSA-N carprofen Chemical compound C1=C(Cl)C=C2C3=CC=C(C(C(O)=O)C)C=C3NC2=C1 PUXBGTOOZJQSKH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- -1 heteroaryl acetic acids Chemical class 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Tratamiento o prevencion de procesos y enfermedades inflamatorias en perros asociadas con la actividad de la ciclo-oxigenasa-2 (COX-2) inducible, mientrasque al mismo tiempo se reducen o eliminan los efectos secundarios indeseables asociados conla inhibicion simultánea de la actividad de la ciclo-oxigenasa-1(COX-1) constitutiva, mediante la inhibicion selectiva de la actividad de COX-2 con respecto a la actividad de la COX-1, donde la relacionde selectividadde COX-2:COX-1 es al menos3: 1 basándose en los niveles de inhibicion ex vivo medidos en sangre entera; el inhibidor es un miembro seleccionado entre elgrupo de compuestos anti-inflamatorios que consta esencialmente de derivados del ácido salicílico; derivados dep-aminofen ol; ácidos indol e idenoacéticos;ácidos heteroaril acéticos; ácidos arilpropionicos; ácidos antranílicos; ácidos enolicos; y alcanonas; el inhibidor, en particular, está compuesto por elenantiomero (-) (S) del ácido6-cloro-alfa-metil-9H-carbazol-2- acético.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4563597P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR011726A1 true AR011726A1 (es) | 2000-08-30 |
Family
ID=21939053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102089A AR011726A1 (es) | 1997-05-05 | 1998-05-05 | Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento |
| ARP030101251A AR039628A2 (es) | 1997-05-05 | 2003-04-09 | Formulacion masticable de carprofeno, implante y composicion terapeutica |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101251A AR039628A2 (es) | 1997-05-05 | 2003-04-09 | Formulacion masticable de carprofeno, implante y composicion terapeutica |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP0988034A1 (es) |
| JP (1) | JP2000513020A (es) |
| KR (2) | KR20040004406A (es) |
| CN (1) | CN1255059A (es) |
| AP (1) | AP9801234A0 (es) |
| AR (2) | AR011726A1 (es) |
| AU (1) | AU6932198A (es) |
| BG (1) | BG103852A (es) |
| BR (1) | BR9808720A (es) |
| CA (1) | CA2288759A1 (es) |
| DZ (1) | DZ2479A1 (es) |
| EA (1) | EA003696B1 (es) |
| GT (1) | GT199800063A (es) |
| HR (1) | HRP980244A2 (es) |
| HU (1) | HUP0001286A3 (es) |
| ID (1) | ID21311A (es) |
| IL (1) | IL132570A0 (es) |
| IS (1) | IS5220A (es) |
| MA (1) | MA26491A1 (es) |
| NO (1) | NO995389L (es) |
| NZ (1) | NZ500183A (es) |
| OA (1) | OA11213A (es) |
| PA (1) | PA8450601A1 (es) |
| PE (1) | PE72599A1 (es) |
| PL (1) | PL337003A1 (es) |
| SK (1) | SK148199A3 (es) |
| TN (1) | TNSN98059A1 (es) |
| TW (1) | TW590773B (es) |
| UY (1) | UY24989A1 (es) |
| WO (1) | WO1998050033A1 (es) |
| YU (1) | YU55899A (es) |
| ZA (1) | ZA983722B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245797B1 (en) | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| AU2003204888B2 (en) * | 1998-05-22 | 2005-07-28 | Pfizer Products Inc. | Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives |
| US6506785B2 (en) | 1998-05-22 | 2003-01-14 | Pfizer, Inc. | Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives |
| JP2002528413A (ja) * | 1998-10-23 | 2002-09-03 | メルク フロスト カナダ アンド カンパニー | Ｅ型プロスタグランジンリガンド及びｃｏｘ−２選択的阻害剤を含む配合剤及び使用方法 |
| ATE306263T1 (de) * | 1999-03-10 | 2005-10-15 | Searle Llc | Zusammensetzungen zur verabreichung eines cyclooxygenase-2-hemmers an tiere |
| WO2001034204A1 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| CA2407469A1 (en) * | 2000-05-15 | 2001-11-22 | Merck Frosst Canada & Co. | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor |
| KR20030019422A (ko) | 2000-06-13 | 2003-03-06 | 와이어쓰 | Ｃｏｘ-２저해제를 함유하는 진통성 및 항-염증성 조성물 |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| ATE420201T1 (de) | 2000-08-07 | 2009-01-15 | Univ Vanderbilt | Nachweis der cox-2 aktivität und von anandamid- metaboliten |
| AU2002354901A1 (en) * | 2001-07-16 | 2003-03-03 | Edward Hogestatt | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
| WO2004098619A2 (en) | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
| WO2005009436A1 (en) * | 2003-07-31 | 2005-02-03 | Pharmacia & Upjohn Company Llc | Dispersible formulation of an anti-inflammatory agent |
| WO2006123247A2 (en) * | 2005-05-20 | 2006-11-23 | Pfizer Limited | Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands |
| EP2061440A2 (en) | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| CA2942083C (en) | 2007-04-26 | 2019-01-29 | Sigmoid Pharma Limited | Manufacture of multiple minicapsules |
| CN102470106B (zh) | 2009-05-18 | 2015-09-23 | 希格默伊德药业有限公司 | 包含油滴的组合物 |
| CA2770570A1 (en) | 2009-08-12 | 2011-02-17 | Sigmoid Pharma Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| KR102270323B1 (ko) | 2014-03-06 | 2021-06-29 | 아라타나 세라퓨틱스, 인크. | 그라피프란트의 조성물 및 이를 사용하기 위한 방법 |
| BR112017009510A2 (pt) | 2014-11-07 | 2017-12-19 | Sigmoid Pharma Ltd | composições compreendendo ciclosporina |
| WO2016112312A1 (en) * | 2015-01-09 | 2016-07-14 | Jaguar Animal Health | Methods of treating diarrhea in companion animals |
| EP4125874A4 (en) * | 2020-03-25 | 2024-05-01 | SRI International | LIPOXYGENASE INHIBITORS |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| KR102404883B1 (ko) | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
| CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
-
1998
- 1998-03-02 DZ DZ980089A patent/DZ2479A1/xx active
- 1998-04-30 TW TW087106689A patent/TW590773B/zh not_active IP Right Cessation
- 1998-05-01 YU YU55899A patent/YU55899A/sh unknown
- 1998-05-01 HU HU0001286A patent/HUP0001286A3/hu unknown
- 1998-05-01 JP JP10547869A patent/JP2000513020A/ja active Pending
- 1998-05-01 WO PCT/IB1998/000662 patent/WO1998050033A1/en not_active Ceased
- 1998-05-01 EP EP98915041A patent/EP0988034A1/en not_active Withdrawn
- 1998-05-01 EA EA199900895A patent/EA003696B1/ru not_active IP Right Cessation
- 1998-05-01 SK SK1481-99A patent/SK148199A3/sk unknown
- 1998-05-01 AU AU69321/98A patent/AU6932198A/en not_active Abandoned
- 1998-05-01 IL IL13257098A patent/IL132570A0/xx unknown
- 1998-05-01 KR KR10-2003-7005258A patent/KR20040004406A/ko not_active Ceased
- 1998-05-01 CN CN98804845A patent/CN1255059A/zh active Pending
- 1998-05-01 ID IDP980651A patent/ID21311A/id unknown
- 1998-05-01 BR BR9808720-7A patent/BR9808720A/pt not_active IP Right Cessation
- 1998-05-01 KR KR1019997010252A patent/KR20010012300A/ko not_active Ceased
- 1998-05-01 PL PL98337003A patent/PL337003A1/xx unknown
- 1998-05-01 NZ NZ500183A patent/NZ500183A/en unknown
- 1998-05-01 CA CA002288759A patent/CA2288759A1/en not_active Abandoned
- 1998-05-04 GT GT199800063A patent/GT199800063A/es unknown
- 1998-05-04 UY UY24989A patent/UY24989A1/es not_active Application Discontinuation
- 1998-05-04 MA MA25059A patent/MA26491A1/fr unknown
- 1998-05-04 ZA ZA9803722A patent/ZA983722B/xx unknown
- 1998-05-04 PE PE1998000335A patent/PE72599A1/es not_active Application Discontinuation
- 1998-05-04 AP APAP/P/1998/001234A patent/AP9801234A0/en unknown
- 1998-05-04 TN TNTNSN98059A patent/TNSN98059A1/fr unknown
- 1998-05-05 HR HR60/045,635A patent/HRP980244A2/hr not_active Application Discontinuation
- 1998-05-05 AR ARP980102089A patent/AR011726A1/es unknown
- 1998-05-05 PA PA19988450601A patent/PA8450601A1/es unknown
-
1999
- 1999-10-19 IS IS5220A patent/IS5220A/is unknown
- 1999-11-02 OA OA9900242A patent/OA11213A/en unknown
- 1999-11-03 BG BG103852A patent/BG103852A/xx unknown
- 1999-11-04 NO NO995389A patent/NO995389L/no not_active Application Discontinuation
-
2003
- 2003-04-09 AR ARP030101251A patent/AR039628A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011726A1 (es) | Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento | |
| TR200003583T2 (tr) | Yeni 3-aril propiyonik asit türevleri ve benzerleri. | |
| ES2233931T3 (es) | Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos. | |
| ES2159851T3 (es) | Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa. | |
| PT1039895E (pt) | Utilizacao de acidos 3-benzoilfenilaceticos respectivos esteres ou amidas para o tratamento do glaucoma glc1a | |
| MX9307779A (es) | Compuestos benzoicos fundidos. | |
| DE69932414D1 (de) | Indole-3-propionsäure, ihre salze und ester als arzneimittel | |
| FI863976A0 (fi) | Terapeutisk komposition. | |
| RU95112575A (ru) | Соль арилпропионовой кислоты, способ ее получения и фармацевтическая композиция | |
| ES2171933T3 (es) | Derivados de androsteno. | |
| ES2126684T3 (es) | Utilizacion de derivados de acidos carboxilicos aromaticos para la preparacion de medicamentos. | |
| AR000357A1 (es) | Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico | |
| ES2163805T3 (es) | Derivados de acidos benzofurano-acrilicos y su utilizacion como moduladores de los receptores rxrs o rars. | |
| Brune | Prostaglandins and the mode of action of antipyretic analgesic drugs | |
| Oka et al. | Involvement of peroxynitrite and hydroxyradical generated from nitric oxide in hypoxia/reoxygenation injury in rat cerebrocortical slices | |
| ES2124861T3 (es) | Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa. | |
| PT880520E (pt) | Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase | |
| ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. | |
| HN1997000070A (es) | Inhibición de las metaloproteinasas de matriz por acidos 2-((1)-aroilalquil) -4-biaril-4-oxoburiticos | |
| ES2133390T3 (es) | Derivados de triazolopirimidinas antagonistas de los receptores de la angiotensina ii. | |
| DK0853476T5 (da) | Nimesulidholdigt farmaceutisk præparat til topisk anvendelse | |
| CO5021216A1 (es) | Carprofeno selectivo para cox-2, para el tratamiento del dolor e inflamacion en perros | |
| GT199900171A (es) | Concentrado oral de sertralina. | |
| Peskar et al. | Interaction of cyclooxygenase-2 inhibitors and salicylate in gastric mucosal damage | |
| ES2184150T3 (es) | Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |